Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DV0013 Zilucoplan Auto-Injector Use in Generalized Myasthenia Gravis
2023-508287-30-00Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of zilucoplan in myasthenia gravis (MG), sponsored by UCB. Started Jul 2024; status: completed.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2023-508287-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508287-30-00.